Fractyl Health, Inc. (NASDAQ:GUTS – Get Free Report) CEO Harith Rajagopalan sold 90,972 shares of the company’s stock in a transaction on Friday, January 31st. The stock was sold at an average price of $1.82, for a total value of $165,569.04. Following the transaction, the chief executive officer now owns 491,329 shares in the company, valued at $894,218.78. This trade represents a 15.62 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Harith Rajagopalan also recently made the following trade(s):
- On Monday, November 11th, Harith Rajagopalan sold 96,517 shares of Fractyl Health stock. The shares were sold at an average price of $2.47, for a total value of $238,396.99.
Fractyl Health Price Performance
Fractyl Health stock opened at $1.64 on Thursday. The company has a quick ratio of 5.57, a current ratio of 5.58 and a debt-to-equity ratio of 0.60. Fractyl Health, Inc. has a 52-week low of $1.52 and a 52-week high of $11.55. The firm has a market cap of $78.88 million and a PE ratio of -0.13. The company’s 50 day moving average is $2.03 and its two-hundred day moving average is $2.47.
Hedge Funds Weigh In On Fractyl Health
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Renaissance Technologies LLC acquired a new stake in Fractyl Health in the second quarter valued at approximately $61,000. SG Americas Securities LLC purchased a new stake in shares of Fractyl Health in the 3rd quarter valued at approximately $33,000. Beta Wealth Group Inc. acquired a new stake in shares of Fractyl Health in the 3rd quarter valued at $44,000. Massachusetts Financial Services Co. MA lifted its position in shares of Fractyl Health by 4.9% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 1,045,672 shares of the company’s stock worth $2,646,000 after purchasing an additional 49,289 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its stake in shares of Fractyl Health by 56.9% during the third quarter. Charles Schwab Investment Management Inc. now owns 80,664 shares of the company’s stock worth $204,000 after purchasing an additional 29,262 shares in the last quarter.
Analysts Set New Price Targets
Separately, Morgan Stanley dropped their target price on Fractyl Health from $18.00 to $10.00 and set an “overweight” rating for the company in a research report on Monday.
View Our Latest Stock Analysis on Fractyl Health
Fractyl Health Company Profile
Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.
Recommended Stories
- Five stocks we like better than Fractyl Health
- 5 Top Rated Dividend Stocks to Consider
- 3 Must-Have ETFs Set to Dominate This Quarter
- Find and Profitably Trade Stocks at 52-Week Lows
- Seeking Stability? These 3 Stocks Offer Strong Potential
- What is the S&P 500 and How It is Distinct from Other Indexes
- Trade War Bargain Stocks: Top 3 Picks Too Good to Pass Up
Receive News & Ratings for Fractyl Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fractyl Health and related companies with MarketBeat.com's FREE daily email newsletter.